CN1305853C - Hmg辅酶a还原酶抑制剂的制备方法 - Google Patents

Hmg辅酶a还原酶抑制剂的制备方法 Download PDF

Info

Publication number
CN1305853C
CN1305853C CNB038027402A CN03802740A CN1305853C CN 1305853 C CN1305853 C CN 1305853C CN B038027402 A CNB038027402 A CN B038027402A CN 03802740 A CN03802740 A CN 03802740A CN 1305853 C CN1305853 C CN 1305853C
Authority
CN
China
Prior art keywords
formula
compound
group
phenyl
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CNB038027402A
Other languages
English (en)
Chinese (zh)
Other versions
CN1622937A (zh
Inventor
M·阿克莫格鲁
B·里斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN1622937A publication Critical patent/CN1622937A/zh
Application granted granted Critical
Publication of CN1305853C publication Critical patent/CN1305853C/zh
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Indole Compounds (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CNB038027402A 2002-01-31 2003-01-30 Hmg辅酶a还原酶抑制剂的制备方法 Expired - Lifetime CN1305853C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35378702P 2002-01-31 2002-01-31
US60/353,787 2002-01-31

Publications (2)

Publication Number Publication Date
CN1622937A CN1622937A (zh) 2005-06-01
CN1305853C true CN1305853C (zh) 2007-03-21

Family

ID=27663254

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB038027402A Expired - Lifetime CN1305853C (zh) 2002-01-31 2003-01-30 Hmg辅酶a还原酶抑制剂的制备方法

Country Status (22)

Country Link
US (2) US7371865B2 (https=)
EP (1) EP1472228B1 (https=)
JP (1) JP4524111B2 (https=)
KR (1) KR20040081161A (https=)
CN (1) CN1305853C (https=)
AT (1) ATE426594T1 (https=)
AU (1) AU2003226971B2 (https=)
BR (1) BR0307303A (https=)
CA (1) CA2472776C (https=)
CO (1) CO5601005A2 (https=)
DE (1) DE60326819D1 (https=)
EC (1) ECSP045214A (https=)
ES (1) ES2323267T3 (https=)
IL (1) IL162980A (https=)
MX (1) MXPA04007396A (https=)
NO (1) NO327091B1 (https=)
NZ (1) NZ534232A (https=)
PL (1) PL370658A1 (https=)
PT (1) PT1472228E (https=)
RU (1) RU2299196C2 (https=)
WO (1) WO2003064392A1 (https=)
ZA (1) ZA200405322B (https=)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE202004021379U1 (de) * 2003-02-12 2008-02-21 Ciba Specialty Chemicals Holding Inc. Kristalline Formen von Pitivastatin Calcium
CN100408562C (zh) * 2003-04-24 2008-08-06 大赛璐化学工业株式会社 (3r,5s,6e)-7-[2-环丙基-4-(4-氟苯基)喹啉-3-基]-3,5-二羟基-6-庚烯酸乙酯的制备方法
TWI328006B (en) * 2003-12-26 2010-08-01 Nissan Chemical Ind Ltd Crystal form of quinoline compound and process for its production
WO2006035286A2 (en) * 2004-09-27 2006-04-06 Ranbaxy Laboratories Limited Process for preparating enantiomerically pure fluvastatin sodium and a novel polymorphic form thereof
US8455640B2 (en) * 2006-05-03 2013-06-04 Msn Laboratories Limited Process for statins and its pharmaceutically acceptable salts thereof
US8404841B2 (en) * 2006-10-09 2013-03-26 Msn Laboratories Limited Process for the preparation of statins and their pharmaceutically acceptable salts thereof
US7687660B2 (en) * 2007-04-18 2010-03-30 Teva Pharmaceutical Industries Ltd. Process for preparing intermediates of HMG-CoA reductase inhibitors
US20090069563A1 (en) * 2007-07-12 2009-03-12 Valerie Niddam-Hildesheim Rosuvastatin intermediates and their preparation
US8487105B2 (en) * 2009-01-19 2013-07-16 Msn Laboratories Limited Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof
KR101160152B1 (ko) * 2009-02-24 2012-06-27 한미사이언스 주식회사 스타틴 화합물 또는 그 염의 신규 제조방법, 및 이에 사용되는 중간체 화합물
WO2011086584A2 (en) 2010-01-18 2011-07-21 Msn Laboratories Limited Improved process for the preparation of amide intermediates and their use thereof
WO2011104725A2 (en) * 2010-02-23 2011-09-01 Cadila Healthcare Limited Hmg-coa reductase inhibitors and process for the preparation thereof
EP2383260A3 (en) 2010-04-30 2011-12-28 Dipharma Francis S.r.l. Process for the preparation of statins
WO2011141934A1 (en) 2010-05-13 2011-11-17 Matrix Laboratories Ltd. An improved process for the preparation of an intermediate of hmg-coa reductase inhibitors
JP5822169B2 (ja) * 2010-07-01 2015-11-24 ユーハン・コーポレイションＹＵＨＡＮ Ｃｏｒｐｏｒａｔｉｏｎ ＨＭＧ−ＣｏＡ還元酵素阻害剤及びその中間体の製造方法
EP3178812A1 (en) * 2010-11-12 2017-06-14 Hetero Research Foundation Novel polymorphs of pitavastatin calcium
EP2785851A2 (en) 2011-11-28 2014-10-08 Mylan Laboratories, Limited Process for producing chiral statin side chain intermediates employing candida antarctica lipase b
CN103288871A (zh) * 2012-02-28 2013-09-11 浙江京新药业股份有限公司 一种制备二羟基酸HMG-CoA还原酶抑制剂用的中间体及其制备方法和应用
ITVI20130039A1 (it) 2013-02-20 2014-08-21 F I S Fabbrica Italiana Sint I S P A Processo per la preparazione di intermedi chiave per la sintesi di statine
CN103172656B (zh) * 2013-04-02 2015-07-08 浙江科技学院 3-二甲基叔丁基硅氧基戊二酸酐的合成工艺
CN111518035A (zh) * 2020-06-18 2020-08-11 安徽鼎旺医药有限公司 一种瑞舒伐他汀叔丁胺盐及其制备方法
CN113683539B (zh) * 2021-09-23 2023-05-16 上海裕兰生物科技有限公司 一种聚酮中间体的合成方法

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
US5034399A (en) * 1989-04-06 1991-07-23 Bayer Aktiengesellschaft Substituted 1,8-naphthyridines and their use in medicaments
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5856336A (en) * 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4650890A (en) * 1984-04-03 1987-03-17 Sandoz Corp. Preparation of olefinic compounds and intermediates thereof
CA1336714C (en) 1987-08-20 1995-08-15 Yoshihiro Fujikawa Quinoline type mevalonolactone inhibitors of cholesterol biosynthesis
DK0484614T3 (da) * 1990-05-11 1995-06-12 American Cyanamid Co N-Acylerede arylpyrroler, der kan anvendes som insekticide, akaricide, nematodicide og molluscicide midler
JP3528186B2 (ja) 1991-06-24 2004-05-17 日産化学工業株式会社 光学活性キノリンメバロン酸のジアステレオマー塩
CA2427255A1 (en) * 2000-11-16 2002-06-06 Teva Pharmaceutical Industries Ltd. Hydrolysis of [r(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta. -dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid esters with calcium hydroxide
KR100883874B1 (ko) * 2001-02-02 2009-02-17 미쯔비시 가가꾸 가부시끼가이샤 (3ｒ,5ｓ)-(ｅ)-7-[2-시클로프로필-4-(4-플루오로페닐)-퀴노린-3-일]-3,5-디하이드록시헵트-6-엔산 에스테르류의 제조방법
EP1466905B1 (en) * 2001-11-14 2011-05-18 Nissan Chemical Industries, Ltd. Process for producing optically active oxoheptenoic acid ester
US6835838B2 (en) * 2002-01-28 2004-12-28 Novartis Ag Process for the manufacture of organic compounds
GB0210234D0 (en) * 2002-05-03 2002-06-12 Novartis Ag Process for the manufacture of organic compounds

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5354772A (en) * 1982-11-22 1994-10-11 Sandoz Pharm. Corp. Indole analogs of mevalonolactone and derivatives thereof
US5856336A (en) * 1987-08-20 1999-01-05 Nissan Chemical Industries Ltd. Quinoline type mevalonolactones
US4804770A (en) * 1988-04-29 1989-02-14 E. R. Squibb & Sons, Inc. Process for preparing a keto-phosphonate intermediate useful in preparing HMG-CoA reductase inhibitors
US5034399A (en) * 1989-04-06 1991-07-23 Bayer Aktiengesellschaft Substituted 1,8-naphthyridines and their use in medicaments
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith

Also Published As

Publication number Publication date
US20080182873A1 (en) 2008-07-31
CN1622937A (zh) 2005-06-01
KR20040081161A (ko) 2004-09-20
RU2299196C2 (ru) 2007-05-20
CA2472776C (en) 2011-01-25
EP1472228A1 (en) 2004-11-03
JP2005520814A (ja) 2005-07-14
NO20043611L (no) 2004-08-30
US20050070605A1 (en) 2005-03-31
ATE426594T1 (de) 2009-04-15
PL370658A1 (en) 2005-05-30
PT1472228E (pt) 2009-06-24
ES2323267T3 (es) 2009-07-10
IL162980A (en) 2010-02-17
EP1472228B1 (en) 2009-03-25
MXPA04007396A (es) 2004-10-11
US7371865B2 (en) 2008-05-13
JP4524111B2 (ja) 2010-08-11
BR0307303A (pt) 2005-01-11
NO327091B1 (no) 2009-04-20
RU2004126442A (ru) 2005-06-10
HK1070651A1 (en) 2005-06-24
ECSP045214A (es) 2004-09-28
WO2003064392A1 (en) 2003-08-07
CO5601005A2 (es) 2006-01-31
DE60326819D1 (de) 2009-05-07
AU2003226971B2 (en) 2006-11-30
NZ534232A (en) 2006-03-31
ZA200405322B (en) 2005-07-27
CA2472776A1 (en) 2003-08-07

Similar Documents

Publication Publication Date Title
CN1305853C (zh) Hmg辅酶a还原酶抑制剂的制备方法
CN1215045C (zh) 3,3－二苯基丙胺类化合物的新衍生物的稳定盐
CN1774417A (zh) 17－苯基－18,19,20－去三甲－前列腺素F2α及其衍生物的制备方法
CN1234679C (zh) 3,3－二芳基丙基胺衍生物的简化合成法
CN1308332C (zh) 芳基醚的制备方法
CN1229347C (zh) 制备哌啶衍生物非索非那定的方法
CN1894209A (zh) 前列腺素的合成
CN1036013A (zh) 抗血胆甾醇过高的四唑化合物及其中间体的制备
CN1261428C (zh) 用于生产海绵内酯和海绵内酯类似物的中间体的制备方法
CN1053604A (zh) 氨基甲酰基衍生物
CN1538954A (zh) 用于合成埃坡霉素及其衍生物并经保护的3,5-二羟基-2,2-二甲基-戊腈及其制备方法和应用
CN87107427A (zh) 取代的氨甲基-5，6，7，8-四氢萘氧代乙酸，新的中间体产物，它们的制备过程及其作为药物的应用
CN1214021C (zh) 制备异香豆素及其中间体的方法
CN1102644A (zh) 缩合吡啶型甲羟戊酸内酯中间体及其制备方法
CN1185208C (zh) 邻氯甲基苯基二羟乙酸衍生物的制备方法
CN88102858A (zh) 可用作抗高血压剂的肼衍生物的制备方法
CN1538952A (zh) 用于合成埃坡霉素及其衍生物并经保护的3,5-二羟基-2,2-二甲基-戊酰胺及其制备方法和应用
CN1684945A (zh) 制备中间体的方法
CN1620425A (zh) 制备氨基甲酸2－(取代苯基)－2－羟基－乙酯的方法
CN1184216C (zh) 制备5－氧代－7－氧杂双环[4.1.0]庚－3－烯－3－羧酸酯的方法
CN1221505C (zh) 制备链烷二醇衍生物方法
CN1084166A (zh) 取代的(苯并噻唑基-和喹喔啉基-甲氧基)苯基-乙酸衍生物
CN1146554C (zh) 非甾体抗雌激素的对映体选择性合成
CN1990450A (zh) 前列腺素f型衍生物的制造方法及新颖中间体
CN1095062A (zh) 取代的吡咯烷-2-酮的纯对映异构体制备方法

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: NOVARTIS CO., LTD.

Free format text: FORMER NAME: NOVARTIS AG

CP01 Change in the name or title of a patent holder

Address after: Basel, Switzerland

Patentee after: NOVARTIS AG

Address before: Basel, Switzerland

Patentee before: Novartis AG

CX01 Expiry of patent term
CX01 Expiry of patent term

Granted publication date: 20070321